Managing Residual Disease After Neoadjuvant Therapy in Breast Cancer

December 14, 2016
Debu Tripathy, MD

Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the dilemma of managing a patient who has residual disease after receiving neoadjuvant therapy.